Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AIM ImmunoTech (AIM) Cash from Financing Activities (2018 - 2025)

Historic Cash from Financing Activities for ImmunoTech (AIM) over the last 11 years, with Q3 2025 value amounting to $6.7 million.

  • ImmunoTech's Cash from Financing Activities rose 475693.43% to $6.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.7 million, marking a year-over-year increase of 5675.19%. This contributed to the annual value of $6.4 million for FY2024, which is 122865.98% up from last year.
  • According to the latest figures from Q3 2025, ImmunoTech's Cash from Financing Activities is $6.7 million, which was up 475693.43% from $355000.0 recorded in Q2 2025.
  • ImmunoTech's 5-year Cash from Financing Activities high stood at $6.7 million for Q3 2025, and its period low was $5000.0 during Q2 2023.
  • Its 3-year average for Cash from Financing Activities is $1.3 million, with a median of $355000.0 in 2025.
  • In the last 5 years, ImmunoTech's Cash from Financing Activities skyrocketed by 4872000.0% in 2024 and then plummeted by 8545.68% in 2025.
  • Over the past 3 years, ImmunoTech's Cash from Financing Activities (Quarter) stood at $147000.0 in 2023, then skyrocketed by 605.44% to $1.0 million in 2024, then skyrocketed by 541.66% to $6.7 million in 2025.
  • Its Cash from Financing Activities stands at $6.7 million for Q3 2025, versus $355000.0 for Q2 2025 and $660000.0 for Q1 2025.